Replacing ranibizumab with bevacizumab on the pharmaceutical benefits scheme: Where does the current evidence leave us?

Clinical and Experimental Optometry

Volumn 95, Issue 5, 2012, Pages 538-540

  Aujla, Jaskirat S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anti VEGF treatments; Bevacizumab; Macular degeneration; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A;

CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION; SINGLE BLIND PROCEDURE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MACULAR DEGENERATION; SINGLE-BLIND METHOD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865567236     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2012.00735.x     Document Type: Note

References (11)

1. Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008; CD005139.
2. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-1279.
3. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
4. Harvey KJ, Day RO, Campbell WG, Lipworth W. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust 2011; 194: 567-568.
5. Mitchell P, Annemans L, White R, Gallagher M, Thomas S. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011; 29: 107-131.
6. Beaumont P. Bevacizumab: not as good with more adverse reactions? Clin Experiment Ophthalmol 2011; 39: 588-590.
7. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
8. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011; 364: 1966-1967.
9. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 2011; 152: 329-331.
10. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002; 105: 766-769.
11. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, Tellides G etal. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010; 107: 408-417.